-
1.发明授权Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use 有权包含FGF18和IL-1拮抗剂的药物组合物及其使用方法公开(公告)号：US07749965B2
公开(公告)日：2010-07-06
申请号：US12103420
申请日：2008-04-15
申请人： Emma E. Moore , Jeff L. Ellsworth
发明人： Emma E. Moore , Jeff L. Ellsworth
CPC分类号： A61K38/1825 , A61K31/722 , A61K31/724 , A61K31/728 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2300/00
摘要： FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.
摘要翻译： 已知FGF18可刺激软骨细胞，骨骼和神经组织的增殖，导致病变组织的修复。 当除FGF18外施用IL-1拮抗剂时，发现对IL-1介导的疾病的影响以及对软骨，骨骼和神经细胞增殖的影响大于施用FGF18或IL- 1拮抗剂。 本发明包括使用该药物组合物将FGF18与IL-1拮抗剂组合的药物组合物和治疗IL-1介导的疾病的方法。
-
2.发明授权Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use 有权包含FGF18和IL-1拮抗剂的药物组合物及其使用方法公开(公告)号：US08084426B2
公开(公告)日：2011-12-27
申请号：US12784377
申请日：2010-05-20
申请人： Emma E. Moore , Jeff L. Ellsworth
发明人： Emma E. Moore , Jeff L. Ellsworth
IPC分类号： A61K38/18
CPC分类号： A61K38/1825 , A61K31/722 , A61K31/724 , A61K31/728 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2300/00
摘要： FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.
摘要翻译： 已知FGF18可刺激软骨细胞，骨骼和神经组织的增殖，导致病变组织的修复。 当除FGF18外施用IL-1拮抗剂时，发现对IL-1介导的疾病的影响以及对软骨，骨骼和神经细胞增殖的影响大于施用FGF18或IL- 1拮抗剂。 本发明包括使用该药物组合物将FGF18与IL-1拮抗剂组合的药物组合物和治疗IL-1介导的疾病的方法。
-
3.发明申请PHARMACEUTICAL COMPOSITION COMPRISING FGF18 AND IL-1 ANTAGONIST AND METHOD OF USE 有权包含FGF18和IL-1拮抗剂的药物组合物及其使用方法公开(公告)号：US20100291212A1
公开(公告)日：2010-11-18
申请号：US12784377
申请日：2010-05-20
申请人： Emma E. Moore , Jeff L. Ellsworth
发明人： Emma E. Moore , Jeff L. Ellsworth
CPC分类号： A61K38/1825 , A61K31/722 , A61K31/724 , A61K31/728 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2300/00
摘要： FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.
摘要翻译： 已知FGF18可刺激软骨细胞，骨骼和神经组织的增殖，导致病变组织的修复。 当除FGF18外施用IL-1拮抗剂时，发现对IL-1介导的疾病的影响以及对软骨，骨骼和神经细胞增殖的影响大于施用FGF18或IL- 1拮抗剂。 本发明包括使用该药物组合物将FGF18与IL-1拮抗剂组合的药物组合物和治疗IL-1介导的疾病的方法。
-
4.发明申请PHARMACEUTICAL COMPOSITION COMPRISING FGF18 AND IL-1 ANTAGONIST AND METHOD OF USE 有权包含FGF18和IL-1拮抗剂的药物组合物及其使用方法公开(公告)号：US20080193501A1
公开(公告)日：2008-08-14
申请号：US12103420
申请日：2008-04-15
申请人： Emma E. Moore , Jeff L. Ellsworth
发明人： Emma E. Moore , Jeff L. Ellsworth
IPC分类号： A61K38/18 , A61K39/395 , A61K9/10 , A61F2/00 , A61P19/02
CPC分类号： A61K38/1825 , A61K31/722 , A61K31/724 , A61K31/728 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2300/00
摘要： FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.
摘要翻译： 已知FGF18可刺激软骨细胞，骨骼和神经组织的增殖，导致病变组织的修复。 当除FGF18外施用IL-1拮抗剂时，发现对IL-1介导的疾病的影响以及对软骨，骨骼和神经细胞增殖的影响大于施用FGF18或IL- 1拮抗剂。 本发明包括使用该药物组合物将FGF18与IL-1拮抗剂组合的药物组合物和治疗IL-1介导的疾病的方法。
-
公开(公告)号：US08507430B2
公开(公告)日：2013-08-13
申请号：US12104285
申请日：2008-04-16
申请人： Jeff L. Ellsworth
发明人： Jeff L. Ellsworth
IPC分类号： A61K38/18 , A61K31/728 , C07K14/50
CPC分类号： A61K9/0019 , A61K31/728 , A61K38/1825 , A61K45/06 , A61K47/36 , C07C51/38 , C07C67/343 , C07C57/58 , C07C69/65 , A61K2300/00
摘要： FGF18 is known to stimulate the proliferation of chondrocytes, resulting in increased cartilage formation. When hyaluronic acid is administered in addition to FGF18, the effects on chondrocyte proliferation and production of matrix were found to be greater than administration of FGF18 or hyaluronic acid alone.
摘要翻译： 已知FGF18可刺激软骨细胞的增殖，导致软骨形成增加。 当除了FGF18以外施用透明质酸时，发现对软骨细胞增殖和基质产生的影响大于单独施用FGF18或透明质酸。
-
公开(公告)号：US08658766B2
公开(公告)日：2014-02-25
申请号：US12999564
申请日：2009-06-29
申请人： Carl W. Birks , Brian A. Fox , Mark W. Rixon , Jeff L. Ellsworth
发明人： Carl W. Birks , Brian A. Fox , Mark W. Rixon , Jeff L. Ellsworth
CPC分类号： C07K14/70503 , A61K38/00 , C07K14/70535
摘要： Disclosed are soluble hybrid Fcγ receptor (FcγR) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid FcγR polypeptides.
摘要翻译： 公开了可溶性杂合Fcγ受体（FcgammaR）多肽组合物和使用这些多肽治疗IgG介导的和免疫复合物介导的炎症的相关方法。 还公开了用于产生可溶性杂合FcγAMR多肽的相关组合物和方法。
-
公开(公告)号：US20080193425A1
公开(公告)日：2008-08-14
申请号：US12104285
申请日：2008-04-16
申请人： Jeff L. Ellsworth
发明人： Jeff L. Ellsworth
CPC分类号： A61K9/0019 , A61K31/728 , A61K38/1825 , A61K45/06 , A61K47/36 , C07C51/38 , C07C67/343 , C07C57/58 , C07C69/65 , A61K2300/00
摘要： FGF18 is known to stimulate the proliferation of chondrocytes, resulting in increased cartilage formation. When hyaluronic acid is administered in addition to FGF18, the effects on chondrocyte proliferation and production of matrix were found to be greater than administration of FGF18 or hyaluronic acid alone.
摘要翻译： 已知FGF18可刺激软骨细胞的增殖，导致软骨形成增加。 当除了FGF18以外施用透明质酸时，发现对软骨细胞增殖和基质产生的影响大于单独施用FGF18或透明质酸。
-
公开(公告)号：US06355788B1
公开(公告)日：2002-03-12
申请号：US09412554
申请日：1999-10-05
IPC分类号： C07H2104
CPC分类号： C07K14/4703 , A61K38/00 , C07K2319/02
摘要： The present invention relates to polynucleotide and polypeptide molecules for zfsta2, a novel member of the follistatin family. The polypeptides, and polynucleotides encoding them are useful for binding to members of the TGF-&bgr; family and mediating central nervous system, reproductive, hematopoietic and bone-related activities. The present invention also includes antibodies to the zfsta2 polypeptides.
摘要翻译： 本发明涉及zfsta2的多核苷酸和多肽分子，卵泡抑素家族的新成员。 多肽和编码它们的多核苷酸可用于结合TGF-β家族的成员并介导中枢神经系统，生殖，造血和骨相关活动。 本发明还包括针对zfsta2多肽的抗体。
-
公开(公告)号：US06242588B1
公开(公告)日：2001-06-05
申请号：US09441346
申请日：1999-11-16
IPC分类号： C07H100
CPC分类号： C07K14/705 , C07K2319/00
摘要： The present invention relates to zpep10 polypeptides and polynucleotides encoding the same. Zpep10 polypeptide is a testis-specific membrane glycoprotein. Zpep10 polypeptides would be useful for modulating spermatogenesis and egg-sperm interaction and would be useful to study or modulate these functions in in vitro or in vivo systems. The present invention also includes antibodies to the zpep10 polypeptides.
摘要翻译： 本发明涉及zpep10多肽及其编码的多核苷酸。 Zpep10多肽是睾丸特异性膜糖蛋白。 Zpep10多肽可用于调节精子发生和卵精子相互作用，并且可用于在体外或体内系统中研究或调节这些功能。 本发明还包括对zpep10多肽的抗体。
-
公开(公告)号：US20110217291A1
公开(公告)日：2011-09-08
申请号：US12999564
申请日：2009-06-29
申请人： Carl W. Birks , Brian A. Fox , Mark W. Rixon , Jeff L. Ellsworth
发明人： Carl W. Birks , Brian A. Fox , Mark W. Rixon , Jeff L. Ellsworth
IPC分类号： A61K39/395 , C12N15/63 , C12P21/02 , C12N5/10 , C07K16/42 , C12N1/00 , C07H21/00 , A61P29/00 , A61P19/02
CPC分类号： C07K14/70503 , A61K38/00 , C07K14/70535
摘要： Disclosed are soluble hybrid Fcγ receptor (FcγR) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid FcγR polypeptides.
摘要翻译： 公开了可溶性杂合Fcγ受体（FcγR）多肽组合物和使用这些多肽治疗IgG介导的和免疫复合物介导的炎症的相关方法。 还公开了用于产生可溶性杂合FcγR多肽的相关组合物和方法。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.02 秒)
